BiomX Inc
For the period ended Dec 31, 2023. Filed Apr 4, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 4, 2024
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
**CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| CASH FLOWS – OPERATING ACTIVITIES | ||
| Net loss | (26,169) | (28,317) |
| Adjustments required to reconcile net loss to cash flows used in operating activities | ||
| Depreciation and amortization | 871 | 2,520 |
| Stock-based compensation | 1,059 | 1,529 |
| Amortization of debt issuance costs | 567 | 463 |
| Finance income, net | (128) | (842) |
| Changes in other liabilities | (33) | (27) |
| Capital loss, net | 71 | 10 |
| Changes in operating assets and liabilities: | ||
| Other current assets | 819 | 956 |
| Trade account payables | 556 | (1,975) |
| Other account payables | 1,194 | (3,303) |
| Net change in operating leases | (93) | (106) |
| Net cash used in operating activities | (21,286) | (29,092) |
| CASH FLOWS – INVESTING ACTIVITIES | ||
| Investment in short-term deposits | - | (13,500) |
| Proceeds from short -term deposits | 2,000 | 11,500 |
| Purchase of property and equipment | (50) | (112) |
| Proceeds from sale of property and equipment | 1 | 5 |
| Net cash provided by (used in) investing activities | 1,951 | (2,107) |
| CASH FLOWS – FINANCING ACTIVITIES | ||
| Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs | - | 273 |
| Issuance of Common Stock and warrants under PIPE | 7,485 | - |
| Issuance costs from PIPE | (333) | - |
| Repayment of long-term debt | (4,253) | - |
| Proceeds on account of shares | - | 19 |
| Net cash provided by financing activities | 2,899 | 292 |
| Decrease in cash and cash equivalents and restricted cash | (16,436) | (30,907) |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 6 | 106 |
| Cash and cash equivalents and restricted cash at the beginning of the year | 32,294 | 63,095 |
| Cash and cash equivalents and restricted cash at the end of the year | 15,864 | 32,294 |
**CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS: | ||
| Cash and cash equivalents | 14,907 | 31,332 |
| Restricted cash | 957 | 962 |
| Total cash and cash equivalents and restricted cash | 15,864 | 32,294 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
| Cash paid for interest | 1,873 | 1,554 |
| Taxes paid | 54 | 65 |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES: | ||
| Property and equipment purchases included in accounts payable | 5 | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.